Italfarmaco's Givinostat Encouraging In DMD, But Awaiting 2022 Pivotal Study Results

CMO Bettica Outlines Development Approach

Piazza del Duomo, Milan, Italy
Milan, where Italfarmaco is based • Source: Shutterstock/Viacheslav Lopatin
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Rare Diseases

More from Scrip